News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
Presentation AHA 2024 Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial Presenter: Marcely Gimenes Bonatto November 18, 2024
News Conference News AHA 2024 ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH Caitlin E. Cox November 18, 2024
News Daily News CMS Announces Negotiated Medicare Prices for First 10 Drugs Yael L. Maxwell August 16, 2024
News Daily News Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds L.A. McKeown February 23, 2024
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ESC 2021 Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention Michael O'Riordan August 31, 2021
News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Daily News Nighttime Hypertension Drug Dosing May Reduce Risk of CVD L.A. McKeown October 23, 2019
News Daily News High-Sensitivity Troponin T May Offer Glimpse Into Future HF Risk: ARIC Analysis L.A. McKeown September 13, 2019
News Daily News PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years Todd Neale August 23, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Features Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis? Michael O'Riordan February 01, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2018 Shelley Wood November 30, 2018
News Daily News Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete? Michael O'Riordan June 05, 2017
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017